Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 6/20 | 0.52 |
| ▸ | SSTR3 | P32745 | 5/20 | 0.52 |
| ▸ | SSTR4 | P31391 | 4/20 | 0.52 |
| ▸ | SSTR2 | P30874 | 3/20 | 0.52 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5841003 | 1.00 | SSTR5 (0.52) | SSTR5SSTR3SSTR4SSTR2SSTR1 | |
| SCHEMBL22053387 | 1.00 | SSTR5 (0.52) | SSTR5SSTR3SSTR4SSTR2SSTR1 | |
| SCHEMBL16632757 | 1.00 | SSTR5 (0.52) | SSTR5SSTR3SSTR4SSTR2SSTR1 | |
| SCHEMBL5840823 | 1.00 | SSTR5 (0.52) | SSTR5SSTR3SSTR4SSTR2SSTR1 | |
| SCHEMBL5840827 | 1.00 | SSTR5 (0.52) | SSTR5SSTR3SSTR4SSTR2SSTR1 | |
| SCHEMBL5841004 | 1.00 | SSTR5 (0.52) | SSTR5SSTR3SSTR4SSTR2SSTR1 | |
| SCHEMBL10525210 | 0.94 | SSTR4 (0.51) | SSTR5SSTR3SSTR4SSTR2SSTR1 | |
| SCHEMBL8894417 | 0.93 | SSTR5 (0.54) | SSTR5SSTR3SSTR4SSTR2SSTR1 | |
| SCHEMBL8894414 | 0.93 | SSTR5 (0.54) | SSTR5SSTR3SSTR4SSTR2SSTR1 | |
| SCHEMBL6760495 | 0.93 | POLB (0.57) | SSTR5SSTR3SSTR4SSTR2SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060281708-A1 | Fluorinated glucosamine analogs useful for modulating post-translational glyscosylations on cells | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2006-12-14 | — | — | US | disclosed |
| US-7098195-B2 | Fluorinated glucosamine analogs useful for modulating post-translational glycosylations on cells | HEALTH RESEARCH, INC. (US) | 2006-08-29 | — | — | US | disclosed |
| EP-1461046-A4 | FLUORINATED GLUCOSAMINE ANALOGS USEFUL FOR MODULATING POST-TRANSLATIONAL GLYCOSYLATIONS ON CELLS | BRIGHAM & WOMENS HOSPITAL (US) | 2005-06-22 | — | — | EP | disclosed |
| EP-1461046-A2 | FLUORINATED GLUCOSAMINE ANALOGS USEFUL FOR MODULATING POST-TRANSLATIONAL GLYCOSYLATIONS ON CELLS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003093410-A2 | FLUORINATED GLUCOSAMINE ANALOGS USEFUL FOR MODULATING POST-TRANSLATIONAL GLYCOSYLATIONS ON CELLS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| US-20030148997-A1 | Fluorinated glucosamine analogs useful for modulating post-translational glycosylations on cells | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-08-07 | — | — | US | disclosed |
| US-6562514-B1 | Stabilized vanadium electrolyte solutions for all-vanadium redox cells and batteries | PINNACLE VRB LIMITED (AU) | 2003-05-13 | — | — | US | disclosed |
| US-6468688-B2 | CHARGING, DISCHARGING EFFICIENCY; VANADIUM ELECTROLYTE | PINNACLE VRB LIMITED (AU) | 2002-10-22 | — | — | US | disclosed |
| US-20010028977-A1 | Charging, discharging efficiency; vanadium electrolyte | JD HOLDING INC. (KY) | 2001-10-11 | — | — | US | disclosed |
| US-6143443-A | ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE | PINNACLE ARB LIMITED (AU) | 2000-11-07 | — | — | US | disclosed |
| EP-0829104-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1998-03-18 | — | — | EP | disclosed |
| EP-0729648-A4 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LTD (AU) | 1997-01-02 | — | — | EP | disclosed |
| WO-1996035239-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-11-07 | — | — | WO | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281708-A1 | Fluorinated glucosamine analogs useful for modulating post-translational glyscosylations on cells | B3GAT3, UGGT1, FUT5 | SSTR5 1562/4885SSTR3 2034/4885SSTR4 2379/4885 |
| US-20030148997-A1 | Fluorinated glucosamine analogs useful for modulating post-translational glycosylations on cells | FUT5, FUT6, OGT | SSTR5 1783/4885SSTR3 2499/4885SSTR4 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.